Setup

Clarivate (CLVT) is a $1.8B information services company — Web of Science, Cortellis, Derwent, ProQuest. Subscription model with 92.5% renewal, 4.1x net leverage, three segments (Academia & Government, Intellectual Property, Life Sciences & Healthcare). The Q1 2026 10-Q filed April 29 confirmed the LS&H segment sale process is at "active discussions with interested parties" and disclosed structural margin expansion. Stock is +72% in a month and +14% on filing day. Most of the asymmetric setup that existed at $1.66 has been captured by the tape.

What the filing says

• LS&H sale process active. "We are currently engaged in active discussions with interested parties but cannot assure that the sale process will result in a transaction." LS&H Q1: $93.3M revenue, $29.2M Adj. EBITDA (≈$117M annualized), 31.3% margin.
• Margin expansion is structural. Adj. EBITDA margin 41.2% Q1 2026 vs 39.3% Q1 2025 (+190 bps). Cost of revenue -7.2% on revenue -1.4%. Royalties and product costs fell $12.1M YoY as low-margin wind-downs flow through. IP segment margin reached 43.3% (+240 bps) on declining organic revenue — operating leverage from cost actions, not volume.
• Subscription metrics stable. Annual renewal rate 92.5% (identical to Dec 31 2025). Organic ACV +1.6% vs March 2025 (vs FY2025 +1.8%, slight decel). Deferred revenues $1,019M total (+$120M from year-end).
• Debt actively managed. Total debt $4.33B (-$143M from year-end). 2028 Senior Secured Notes $900M at 3.875%. Bonds trade at ≈88¢ on dollar (fair value $3.82B vs carrying $4.33B). In March 2026, management bought back $42.6M face for $38.5M cash, generating a $3.8M gain.
• Hidden urgency. Revolver ($775M undrawn) has springing maturity 91 days before 2028 notes. Forces management to address the 2028 wall by approximately October 2027.
• Net loss improvement. -$40.2M Q1 2026 vs -$103.9M Q1 2025 (61% YoY improvement). Restructuring expense halved ($24.7M → $12M, with only ≈$13M remaining).
• Securities litigation escalated. Court denied (partially) the motion to dismiss in March 2026. Claims about false organic growth statements survived. Class period 2020-2022. Now in discovery.

What the market thinks

At $2.86: EV ≈$5.85B, EV/EBITDA ≈5.85x vs peers (FDS 20x, MSCI 40x, RELX 17x). Analyst mean target $3.61 (+26%), median $3.00 (+5%). Forward P/E 3.62. Short interest 15.8% of float, 10.2 days to cover. P/C ratio 0.00 with unusual call activity flagged. Some of the +14% one-day move was likely short covering, not pure catalyst re-rating.

Reverse-engineering a two-state collapse (LS&H closes at ≥$4.75 outcome vs fails to ≈$2.20 outcome): market implies ≈26% probability of meaningful deal close. Our prior is 52%. Edge in implied probability ≈26 percentage points — real, but compressed from where it was at $1.66.

Probability-weighted scenario tree:

E[outcome] = $3.86 vs current $2.86 = +35% expected return on 6-12 month horizon. Modal outcome ($2.20, 25% probability) is now BELOW current. P(profit) 57%, P(>50% loss) 8%.

Why the gap exists

Three specific reasons. First, counterparty asymmetry: bondholders price the 2028 notes at 88¢ ("minor refi friction at higher rates") while equity holders price 5.85x EBITDA ("distress premium"). Two informed counterparties pricing the same balance sheet at incompatible levels. Management buying back $42.6M face at 88¢ in March is the insider tell — that's the CFO confirming the bond market view, not the equity market view. Second, the cost-of-revenue line item that drives +190 bps structural margin expansion is in the P&L footnote, not headline. Sell-side models anchor to FY2024 margins (38-39%), while wind-down savings have shifted the structural baseline toward 41%+. Third, the revolver springing maturity (91 days before 2028 notes) is in the credit agreement footnote, not management commentary. Retail and most sell-side reports don't track it. The hidden urgency is what forces the LS&H process to resolve before October 2027.

The cross-ticker corroboration tightens the deal thesis. Healthcare-data M&A precedents support proceeds in $900M-$1.5B range: KKR/Veritas+Cotiviti $11B at 9.4x (May 2024), IQVIA+Cedar Gate $750M at 22.7x (Oct 2025). Norstella + Hg/Warburg PE consortium is the cleanest buyer fit — Citeline-Cortellis competitive overlap, sub-scale to bid solo, PE backers fund the deal. Morgan Stanley confirmed as financial advisor.

Risks (ranked)

1. LS&H sale process stalls past Q3 2026. No signed PSA, no named bidder, no carve-out audited financials. Compresses deal-close probability from 52% to <30%, stock gives back most of the one-month rally.
2. Q2 margin reverts to <40%. The +190 bps was Q1 noise rather than structural. FCF compression follows.
3. Renewal rate prints <90% on next disclosure. Validates AI displacement. CLVT growth lag vs peers (+0.6% organic vs SPGI +9%, FDS +5.9%, MORN +10.8%) is the bear's loaded gun — subscription health metric could mask slow customer-quality decay that only reveals on multi-year renewal cycles.
4. Securities class action settlement materially exceeds insurance. Claims about false organic growth survived motion to dismiss; discovery is producing documents from the 2020-2022 class period.
5. Capital markets restrictive at refi window. If LS&H fails AND credit conditions worsen, refinancing 2028 notes adds $30-50M/year in interest expense.

Catalysts

• Late July 2026 (Q2 earnings): margin sustain test, renewal trajectory, LS&H process status update
• Q3 2026: likely LS&H bidder disclosure window (process announced Feb '26 → 6-9 month bid timing typical)
• Dec 31, 2026: LS&H sale close at ≥$700M proceeds
• Mar 2027: FY2026 10-K — full-year margin print, renewal print
• Oct 2027: revolver springing maturity — final binding deadline forces 2028 notes to be addressed

What would change our mind

• LS&H bidder publicly named with proceeds <$700M → fire-sale rather than premium auction; bear case for residual equity
• LS&H carve-out audited financials NOT filed by Q3 2026 → process slower than "active discussions" implies; deal probability compresses
• Q2 2026 renewal rate prints <91% → genuine subscription erosion, AI displacement validates
• 2029 notes (separate maturity, $900M at 4.875%) discount widens to >15% → bond market repricing tail risk on second wall
• Insider Form 4 SALES at current levels → contradicts the management bond buyback signal

Evidence